DNAJC21 Mutations Link a Cancer-Prone Bone Marrow Failure Syndrome to Corruption in 60S Ribosome Subunit Maturation by Tummala, H et al.
DNAJC21 Mutations Link a Cancer-Prone Bone Marrow Failure Syndrome
to Corruption in 60S Ribosome Subunit Maturation.
Tummala, H; Walne, AJ; Williams, M; Bockett, N; Collopy, L; Cardoso, S; Ellison, A; Wynn,
R; Leblanc, T; Fitzgibbon, J; Kelsell, DP; van Heel, DA; Payne, E; Plagnol, V; Dokal, I;
Vulliamy, T
 
 
 
 
 
Copyright © 2016. Published by Elsevier Inc.
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/15700
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
1 
 
DNAJC21 mutations link a cancer prone bone marrow failure syndrome to corruption 
in 60S ribosome subunit maturation 
Hemanth Tummala1, Amanda J Walne1, Mike Williams2, Nicholas Bockett1, Laura Collopy1, 
Shirleny Cardoso1, Alicia Ellison1, Rob Wynn3,  Thierry Leblanc4, Jude Fitzgibbon5,  David 
P Kelsell6, David A van Heel1, Elspeth Payne7, Vincent Plagnol8, Inderjeet Dokal1* and Tom 
Vulliamy1*† 
Running Title: DNAJC21 mutations cause bone marrow failure 
1Centre for Genomics and Child Health, Blizard Institute, Barts and The London School of 
Medicine and Dentistry, Queen Mary University of London, London, E1 2AT, UK; 2Clinical 
and Laboratory Haematology, Birmingham Children’s Hospital, Birmingham, B4 6NH, UK;  
3Blood and Marrow Transplant Unit, Royal Manchester Children’s Hospital, Manchester, 
M13 9WL, UK; 4Pediatric Hematology, Hôpital Robert-Debré, APHP, Paris, 75019, France; 
5Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen 
Mary University of London, London, EC1M 6BQ, UK; 6Centre for Cell Biology and 
Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and 
Dentistry, Queen Mary University of London, London, E1 2AT, UK; 7UCL Cancer Institute, 
72 Huntley Street, London, WC1E 6DD, UK; 8UCL Genetics Institute, Gower Place, 
London, WC1E 6DD, UK.  
*Joint senior authors 
†Author of Correspondence: 
Professor Tom Vulliamy 
Blizard Institute, Centre for Genomics and Child Health 
Barts and The London School of Medicine and Dentistry 
Queen Mary University of London 
4 Newark Street, London, E1 2AT, UK 
Tel: +44 (0) 207 882 2623; Fax: +44 (0) 207 882 2195; email: t.vulliamy@qmul.ac.uk 
 
2 
 
 
A substantial number of cases with bone marrow failure (BMF) present with one or 
more extra-hematopoietic abnormality. This suggests a constitutional or inherited basis, 
and yet many of them do not fit the diagnostic criteria of the known BMF syndromes. 
Through exome sequencing, we have now identified a sub group of these cases, defined 
by germline biallelic mutations in DNAJC21 (DNAJ homolog subfamily C member 21). 
They present with global bone marrow failure and one individual developed a 
hematological cancer (acute myeloid leukemia) in childhood. We show that the encoded 
protein associates with ribosomal RNA (rRNA) and plays a highly conserved role in the 
maturation of the 60S ribosomal subunit. Lymphoblastoid cells obtained from an 
affected individual exhibit increased sensitivity to the transcriptional inhibitor 
actinomycin D and reduced levels of rRNA. Characterisation of mutations revealed 
impairment in interactions with cofactors (PA2G4, HSPA8 and ZNF622) involved in 
60S maturation. DNAJC21 deficiency resulted in cytoplasmic accumulation of the 60S 
nuclear export factor PA2G4, aberrant ribosome profiles and increased cell death. 
Collectively these findings demonstrate that mutations in DNAJC21 cause a cancer 
prone BMF syndrome due to corruption of early nuclear rRNA biogenesis and late 
cytoplasmic maturation of the 60S subunit. 
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Introduction 
Inherited bone marrow failure (BMF) syndromes are a heterogeneous group of life 
threatening disorders characterized by a hematopoietic defect in association with a range of 
variable extra hematopoietic features. Recognized syndromes include Fanconi anemia [MIM 
227650],1 dyskeratosis congenita [MIM305000],2 Shwachman Diamond syndrome 
[MIM260400] 3 and Diamond Blackfan anemia [MIM105650].4 Cells from Fanconi anemia 
cases exhibit increased chromosomal breakage due to specific genetic and/or functional 
defects causing genome instability.1 Dyskeratosis congenita cases are characterized by 
diagnostic mucocutaneous features such as abnormal skin pigmentation, nail dystrophy and 
leukoplakia together with the presence of very short telomeres.2 Shwachman Diamond 
syndrome is characterized by exocrine pancreatic insufficiency and Diamond Blackfan 
anemia cases are typically reported to have craniofacial abnormalities, including clefting of 
the lip or palate, thumb abnormalities, cardiac malformations, and short stature.5  Importantly, 
these syndromes are also associated with an increased cancer risk.  
 
In addition to the well-defined BMF syndromes, we have accrued a number of cases to our 
BMF registry who do not fit any definite diagnostic classification. These uncharacterized 
cases have BMF together with one or more somatic abnormality suggesting a constitutional 
or inherited basis, but do not fulfil the clinical criteria of the known BMF syndromes. With 
the advent of whole exome sequencing it is now possible to unify subsets of these cases 
through the identification of their underlying genetic defect. This is the case here, as we 
identify a cohort of simplex BMF cases harbouring biallelic mutations in DNAJC21. Through 
characterisation of the encoded protein, we define a cancer prone BMF syndrome caused by 
defective DNAJC21. 
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Materials and Methods 
Study approval. All experiments were conducted with the approval of Barts and The London 
Hospital. Peripheral blood samples were obtained with written consent under the approval of 
our local research ethics committee (London – City and East).  
 
DNA sequencing and plasmids. All samples were obtained with informed, written consent 
and the approval of our local ethics committee. Genomic DNA was extracted from peripheral 
blood using Gentra reagents (Qiagen). For exome sequencing, 50ng of genomic DNA 
underwent library preparation and exome capture using the Illumina Nextera Rapid capture 
exome kit. Sequencing was performed using the Illumina HiSeq 2000 system and 100bp 
paired end reads were generated and the data processed through the Illumina pipeline. 
Variants were called as described previously.6 Resequencing of DNAJC21 was performed as 
a part of a 32 gene panel, amplified using a TruSeq Custom Amplicon reagent which was 
then prepared for MiSeq sequencing according to the manufacturer’s instructions (Illumina). 
All relevant calls were confirmed by Sanger sequencing. DNAJC21 wildtype and mutant 
expression constructs were obtained by standard cDNA cloning and mutagenesis procedures 
into peGFP-C1 (Clontech) plasmid. 
 
Nuclear rRNA coimmunoprecipitation assay. Dialyzed nuclear extracts from ~ 106 cells 
expressing eGFP alone or eGFP tagged wild type and mutant forms of DNAJC21 were 
subjected to immunoprecipitation with GFP TRAP agarose beads (ChromTek). After 
incubation and stringent washes, immune complexes were treated with DNase I-RNase free 
(Fermentas) for 30 min at 37°C in the presence of RNasein (Invitrogen). The reactions were 
stopped by addition of 2.5 mM EDTA and heating for 10 min at 65°C. 
Coimmunoprecipitated RNA was extracted by Trizol (Invitrogen), purified using RNeasy kit 
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columns (Qiagen) and analysed by reverse-transcription quantitative PCR for precursor 45S 
rRNA using primers indicated in Supplemental Table 3. 
 
Quantitative RTPCR 
RNA from nuclear extracts was purified with TRIzol® reagent (Invitrogen) according to 
manufacturer’s instructions. Reverse transcription was performed with SuperScriptTM III 
Reverse Transcriptase (Invitrogen). Quantitative PCR was carried out on a real-time PCR 
detection system with SYBR® Green (Thermo Fischer) for 45S precursor rRNA, mature 28S, 
18S rRNA in case 4, both parents and 3 unrelated samples as controls. Data presented is 
normalized to GAPDH mRNA levels and expression levels of SNORA63 and SNORA68 were 
determined as internal standard controls. 
 
RNAi studies. All siRNA and shRNA experiments were performed on HeLa cells cultured at 
37°C in 5% CO2 and DMEM (Cambrex), supplemented with L-glutamine, 10% FCS, and 
penicillin/streptomycin antibiotics. Transfections of DNAJC21 siRNA (Sigma Cat No: 
EHU103331) was carried out using 50nM siRNA and Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s protocol; a predesigned non target siRNA (Ambion) was 
used as negative control. Cells were harvested at 72 hours for subsequent analysis. Tet-
pLKO-puro shRNA-expressing plasmids were obtained from Addgene and prepared using a 
protocol adopted from Addgene7 to generate Tet-pLKO-puro -DNAJC21 3’UTRshRNA 
specific clones. The specific shRNA sequences of DNAJC21 3’UTR used in this study were 
obtained from the RNAi Consortium (TRC MISSION® shRNA library,) and the RNAi 
designer tool from Thermo Fischer. Target sequences are given in Supplemental Figure 4A. 
DNAJC21 3’UTR shRNA expression was induced by culturing cells in DMEM supplemented 
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with TET free serum (Clontech) for 72 hrs in the presence of the indicated concentrations of 
doxycycline (dox, Sigma, Supplemental Figure 4B) dissolved in deionized water.  
 
Immuno-studies. For co-immunoprecipitation studies, approximately 250 µg cell lysate was 
used per immunoprecipitation in cells transfected with eGFP encoding wild type and mutant 
DNAJC21 plasmids. Briefly, 72 hours post transfection lysates were precleared with rabbit 
control IgG (monoclonal SP137, Abcam) and further incubated with 10 µL anti-GFP 
antibody (Abcam, Cat. No. EPR14104) overnight at 4°C.  For determination of nucleic acid 
mediated interaction, cell lysates were initially treated with 40 U DNase I-RNase free or 25 
µg/mL RNase A for 30 min at 37 °C.  The next day, 20 µL Protein A Dynabeads (Thermo 
Fischer) pre-equilibrated with IP buffer (25 mM Tris-HCl pH 7.9, 5 mM MgCl2, 10 % 
glycerol, 0.1 % NP-40, 1 mM DTT, 1X Complete EDTA-free protease inhibitor cocktail) 
containing 100 mM KCl was added and gently mixed for 2 h at 4 °C. Immune complexes 
were washed three times with IP buffer containing 150 mM KCl and two times with IP buffer 
containing 100 mM KCl, each for 5 min at 4 °C. Immunoprecipitates were boiled in SDS-
sample buffer (25 mM TrisHCl pH 6.8, 2 % SDS, 10 % glycerol, 0.05 % bromophenol blue, 
5 % 2-mercaptoethanol) for 5 min, separated by SDS-polyacrylamide gel electrophoresis 
(PAGE), transferred to polyvinylidene membranes and subject to western blot analysis using 
Western Breeze Chromogenic Kit (Thermo Fischer Cat. No. WB7106, WB7104). Antibodies 
against DNAJC21 (Abcam, Cat. No. ab86434, C-terminal epitope corresponding to amino 
acids 400-450; Protein tech Cat. No. 23411-1-AP, N terminal epitope corresponding to amino 
acids 43-288), PA2G4 (Abcam, Cat. No. ab119037), ZNF622 (Abcam, Cat. No. Ab57859), 
and HSPA8 (Abcam, Cat. No. EP1513Y) were used in the study. For immunocytochemical 
staining, HeLa cells and IMR-90 cells (primary lung fibroblasts obtained from ATCC® CCL-
186™) were grown on coverslips, fixed in 4% paraformaldehyde, permeabilized using 0.1% 
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Triton-X-100 (TX100) in PBS, quenched in 50mM NH4Cl and blocked in 10% goat serum, 
1% BSA in PBS containing 0.05% TX100 for 1 hour. Cells were incubated with 
corresponding primary and secondary antibodies and mounted using vectashield containing 
DAPI (Vector Labs Cat. No. H-1200). Images were collected using an LSM710 laser 
scanning confocal microscope (Olympus) under relevant excitation and the emitted signals 
were visualized using ‘ZEN’ software (Zeiss). Nucleolar co-staining was determined by 
mouse monoclonal antibody against nucleophosmin (Abcam Cat. No. ab40696), and 
DNAJC21.  
 
Sub-cellular fractionation. DNAJC21 knockdown and control cells were lysed in ice-cold 
HEPES containing 0.1% NP40 and centrifuged at 3,000 rpm and the supernatant was 
collected for extraction of cytoplasmic protein. The pellet containing nuclei were briefly 
washed three times in ice-cold HEPES containing 0.1% NP40  and to the pellet ice-cold 
radioimmunoprecipitation assay buffer (RIPA) containing a cocktail of protease and 
phosphatase inhibitors (Roche Cat. No. 04693116001) was added and sonicated twice for 10 
s at 50% pulse to release nuclear proteins. The final mixture was shaken gently on ice for 15 
min, and the nuclear fraction protein supernatant was obtained by centrifugation at 14,000 g 
for 15 min. Fractionated lysates were verified with antibodies against cytoplasmic GAPDH 
(Abcam Cat. No. EPR16891) and nuclear TATA binding protein (Abcam Cat. No. EPR3826) 
by immunoblotting as described above. 
 
T cell isolation and culture. Blood samples were obtained from case 4 and her unaffected 
heterozygous parents. Peripheral blood mononuclear cells were separated using lymphocyte 
separation medium (Lonza) according to the manufacturer's instructions, washed twice with 
complete RPMI containing 15% FCS and resuspended at 1·0 × 106 cells/ml in RPMI-1640 
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medium + 20% fetal calf serum (FCS; Invitrogen). T-cell mitosis was stimulated by the 
addition of 10 μg/ml of phytohaemagglutinin (PHA; Roche Applied Science). After 48 hrs 
the medium was replaced with fresh RPMI containing 10 units/ml of recombinant human 
interleukin 2 (Invitrogen), and harvested after 14 days. Cells were counted on a 
NucleoCounter YC-100 automated cell counter (ChaemoMetec). EBV-infected LCLs were 
established and grown in RPMI Media 1640 supplemented with penicillin and streptomycin, 
2 mM L-glutamine, and 20% (vol/vol) FBS (Invitrogen). 
 
Polysome analysis. For analysis of monosomes and polysomes, HeLa cells and LCLs were 
grown to confluence, harvested 10 minutes after treatment with 100 mg/mL cycloheximide 
(Sigma), and resuspended in PBS containing 100 µg/mL cycloheximide. Equal numbers of 
cells were lysed in 425 μl of hypotonic buffer [(5 mM Tris-HCl (pH 7.5), 2.5 mM MgCl2, 1.5 
mM KCl and 1x protease inhibitor cocktail (EDTA-free)], with 5 μl of 100 µg/ml CHX, 1 μl 
of 1 M DTT, 100 units of RNase inhibitor. Lysates were vortexed for 5 sec followed by 
addition of 25 μl of 10% Triton X-100 (final concentration 0.5%) and 25 μl of 10% sodium 
deoxycholate (final concentration 0.5%) and vortexed again for 5 sec.  Lysates were then 
centrifuged at 16,000g for 2 minutes and supernatants were layered on 15% to 45% (wt/vol) 
sucrose gradients. The gradients were centrifuged at 36,000 rpm for 4 hours at 4°C in a 
Beckman SW41Ti rotor. The fractionated lysates were serially collected and polysome 
profile peaks were obtained by measuring absorbance at 254 nm. Proteins from these 
fractions were precipitated using 20% (vol/vol) trichloroacetic acid, separated on SDS–PAGE 
gels and transferred to polyvinylidene membranes for immunoblotting. 
 
Cell death and rescue by wild type DNAJC21. After 72 hours of RNAi treatment, cells 
were washed in PBS; propidium iodide (PI) was added to the cell suspension to a final 
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concentration of 5μg/ml and analyzed on an LSRII Flow Cytometer (BD Biosciences). 
Plasmids encoding WT-eGFPDNAJC21 and peGFP-C1 alone were transfected into 
DNAJC21 3’UTR shRNA expressing stable cell lines. 48hrs post transfection cells were FAC 
sorted by gating for eGFP, collected and re-plated in 96 wells in equal number.  It is 
important to note that the shRNA system targets the 3’ UTR of the endogenous DNAJC21 
mRNA. This UTR is absent from the plasmid-derived transcript, resulting in shRNA 
depletion of the endogenous DNAJC21 only upon dox induction. DNAJC21 3’UTR shRNA 
1 (Supplemental Figure 3) was preferred as it showed DNAJC21 knockdown upon dox 
induction at a lower concentration 100ng/ml. 
 
Structural analysis of the DNAJC21 p.Pro32Ala variant. The J domain crystal structure 
(PBD id:  1FAF) was obtained from the Protein Data Bank (PBD) and visualized using 
Swiss-PDB viewer.8 The predicted effects of DNAJC21 p.Pro32Ala substitution were 
generated using this program. 
 
Statistics. Analyses were performed with GraphPad Prism 5.0 software (GraphPad 
Software). Mann-Whitney U test, and 1-way ANOVA with Tukey’s post hoc tests were used 
when appropriate as indicated within the text or Figure legends. Data are presented as the 
means ± SEM unless otherwise indicated. A 2-tailed P value of <0.05 was considered 
significant. 
 
Results 
Biallelic mutations in DNAJC21 cause a bone marrow failure syndrome 
In a cohort of 28 unrelated cases with BMF and non-specific somatic features from our BMF 
registry (Table S1), we sought an underlying genetic basis through exome sequencing. Three 
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of these cases, none of whom had any family history of disease, were found to have 
homozygous likely pathogenic variants in DNAJC21 (RefSeq: NM_001012339.2, Table 1, 
Figures 1A and 1B). Specifically, these were a nonsense variant c.517C>T, p.Arg173* in 
case 1, a splice variant c.983+1G>T in case 2 and a missense variant c.94C>G, p.Pro32Ala in 
case 3. Targeted resequencing of DNAJC21 in a second cohort of 23 similar cases (Table S2) 
identified one further individual (case 4) with a homozygous nonsense variant c.793G>T, 
p.Glu265* (Table 1). Sanger sequencing of parental DNA revealed that this variant 
segregated as an autosomal recessive trait. The four cases with biallelic DNAJC21 mutations 
are similar in clinical presentation (Table 1): they have global BMF associated with 
peripheral pancytopenia and are characterised by intrauterine growth restriction and/or short 
stature. One of them (case 3) developed acute myeloid leukemia, sub-type megakaryocytic 
(AML-M7), aged 12 years (Table 1). 
 
Three of the variants are predicted to cause loss of function (LOF, defined here as nonsense 
or splice variants) and the transcripts containing these nonsense and predicted frameshift 
mutations are likely to undergo nonsense mediated mRNA decay. In the fourth, a missense 
variant (p.Pro32Ala) disrupts the highly conserved histidine-proline-aspartic acid (HPD) 
motif that lies at the heart of a J domain, which defines a family of proteins (Figures 1B and 
1C).9 In silico analysis of the p.Pro32Ala substitution on the tertiary structure of the E coli J 
domain (PDB id: 1FAF) reveals the loss of the distinctive cyclic structure of proline in a loop 
between two α-helices (Figure 1D). This structural alteration to the HPD motif is likely to 
disrupt the interaction of the J domain with its cognate heat shock protein 70 and the 
subsequent stimulation of ATPase.10 To our knowledge, none of the variants have been 
reported previously apart from the splice variant (c.983+1 G>A), which is present only in the 
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heterozygous state in the Exome Aggregation Consortium database at an allele frequency of 
5/120,170.  
 
The Exome Aggregation Consortium database estimates the frequency of LOF alleles in 
DNAJC21 (combining frameshift, nonsense and splice donor/acceptor site variants) at about 
0.1% (123 LOF alleles in ~ 120,000 chromosomes). Hence, a frequency of LOF 
homozygotes and compound heterozygotes is expected to be in the range of 1 per million 
individuals. Not including the likely damaging homozygous missense variant, the observed 
frequency of LOF homozygous cases in our combined cohort (3 out of 51 individuals) 
significantly exceeds this expectation (binomial test p < 10-10). We conclude that the allelic 
series of mutations that we have identified here defines a subgroup of cases with 
constitutional BMF caused by defective DNAJC21.  
 
DNAJC21 is implicated in rRNA biogenesis 
DNAJC21 belongs to the family of DnaJ/heat shock protein 40 chaperone proteins 10 and is 
ubiquitously expressed in human tissues (Figure S1). We found that DNAJC21 was present in 
both cytoplasm and nucleus of HeLa and 293T cells. (Figure 2A) Within the nucleus, it 
localised primarily to the nucleolus in three different cell lines tested (Figure 2B). T 
lymphocytes obtained from one affected individual (case 4) revealed a lack of DNAJC21 
immunoreactivity to an antibody recognising an N-terminal epitope, while the parental 
control T cells stained positive (Figure 2B).  
 
To date, little is known about human DNAJC21 apart from a report that its depletion causes a 
‘miscellaneous’ effect on ribosomal RNA (rRNA) processing in HeLa cells.11 To investigate 
the possible relationship between DNAJC21 and rRNA, HeLa cells were treated with low 
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levels (2nM) of actinomycin D (ActD) that are sufficient to exert its inhibitory effect on 
rRNA synthesis.12 This treatment resulted in a translocation of DNAJC21 from the cytoplasm 
to the nucleus (Figure 2C and D). We also observed that lymphoblastoid cells (LCLs) derived 
from case 4 showed an increased sensitivity to ActD treatment when compared to parent 
controls (Figure 2E). Quantitative RTPCR analysis of nuclear RNA extracts obtained from 
these cells showed a reduction in rRNA levels in the affected individual, when compared to 
both parents and unrelated controls (Figure 2F). These results indicate that DNAJC21 is 
involved in rRNA biogenesis. 
 
Given its nucleolar localisation and response to ActD, we sought to investigate a role for 
DNAJC21 in 45S precursor rRNA binding. We therefore performed native RNA co-
immunoprecipitation experiments on nuclear extracts from HeLa cells expressing wild type 
and mutant forms of green fluorescent protein (GFP) tagged DNAJC21. Levels of ectopically 
expressed GFP tagged proteins were established by immunoblotting using an anti-GFP 
antibody (Figure 3A). Quantitative RTPCR analysis on GFP-TRAP immunoprecipitates 
showed that DNAJC21 associates with the precursor 45S rRNA. The truncated DNAJC21 
mutant (p.Arg173*) failed to bind to precursor 45S rRNA (Figure 3B). Taken together these 
results support the notion that DNAJC21 is indeed a pre-rRNA processing factor,11 as it 
associates with precursor 45S rRNA and is involved in rRNA biogenesis. 
 
DNAJC21 interacts with 60S ribosome maturation factors 
The yeast orthologue of DNAJC21, Jjj1 (Figure S2A) has been studied in some detail.  In 
addition to its role in rRNA processing in the nucleus,13 Jjj1 has been shown to act in the final 
stages of 60S ribosome subunit maturation in the cytoplasm .13-18 Specifically, Jjj1 is 
responsible for the eviction of the 60S nuclear export receptor, Arx1 (human orthologue - 
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proliferation associated protein 2G4, PA2G4/ Erbb3 binding protein, EBP1/ IRES specific 
cellular transacting factor 45, ITAF45 (Figure S2B).
19-21 In order to execute this function, Jjj1 
acts in concert with Rei1 (human orthologue - zinc finger protein 622, ZNF622, Figure S2C), 
binding to the 60S subunit. Together, Jjj1 and Rei1 recruit Ssa1p (human orthologue - heat 
shock 70kDa protein 8, HSPA8, Figure S2D) to stimulate ATPase activity. This takes place 
in the cytoplasm, allowing Arx1 to recycle back into the nucleus to aid in further rounds of 
60S nuclear export (Figure S3).  
 
To determine whether these interactions also occurred in humans, we expressed eGFP-tagged 
wild type and mutant forms of DNAJC21 in HeLa cells. Co-immunopreciptation experiments 
revealed the predicted interactions of DNAJC21 with PA2G4, ZNF622 and HSPA8 (Figure 
3C). These interactions were not mediated by nucleic acids since they were detected in both 
DNaseI and RNaseA treated cell lysates (Figure 3C). In contrast, expression of the truncation 
mutant (p.Arg173*) revealed no detectable interaction with any of the aforementioned 
proteins (Figure 3D). We note that it is likely that in vivo, the transcript encoding p.Arg173* 
undergoes nonsense mediated decay and the variant is included in these studies as a negative 
control. The missense variant (p.Pro32Ala) did interact with PA2G4 and ZNF622, but failed 
to interact with HSPA8 (Figure 3D). This is consistent with studies in yeast, which have 
shown that mutation of the HPD motif in Jjj1 results in loss of interaction with its HSP70 
binding partner, Ssa1p. 13, 15, 17  
 
As these mutants failed to interact with 60S maturation factors, we further investigated the 
role of DNAJC21 in ribosome biogenesis. Immunostudies revealed a dramatic accumulation 
of PA2G4 in the cytoplasm of DNAJC21 knockdown cells as well as T lymphocytes from 
case 4, compared to the predominantly nuclear localisation observed in the relevant controls 
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(Figures 4A-C). This data suggests that loss of DNAJC21 perturbs PA2G4 traffic and is 
consistent with previous studies in yeast, which showed that Arx1 fails to traffic back to the 
nucleus in strains that lack Jjj1.14, 16-18 However, there was no change in the relative 
abundance of PA2G4, ZNF622 and HSPA8 in case 4 LCLs compared to parent controls 
(Figure 4D). Sucrose density centrifugation analysis revealed abnormal polysome profiles in 
case 4 LCLs as well as in DNAJC21 knockdown cells when compared to controls (Figure 
4E). Furthermore, a stark increase in the amount of PA2G4 bound to 60S and 80S peak 
fractions is observed in case 4 LCLs (Figure 4E). Collectively, these observations indicate 
that human DNAJC21 plays a prominent role in the maturation of the 60S ribosome subunit. 
 
Loss of DNAJC21 disrupts cell morphology and inhibits cell growth 
Defective ribosome biogenesis could disrupt protein translation, impairing cellular growth. In 
line with this, knockdown of DNAJC21 induced cell death in HeLa cells (Figure 5A and5 B). 
DNAJC21 knockdown cells also exhibited an unusual morphology with markedly elongated 
cellular morphology (Figure 5C). T cells obtained from case 4 also showed a significant 
impairment in growth rate following mitogenic stimulation with phytohemagglutinin and 
interleukin-2, relative to parental controls (Figure 5D, p = <0.001, Student’s t-Test).  
 
To confirm that the cell death, cytoplasmic accumulation of PA2G4 and altered morphology 
were a consequence of DNAJC21 deficit, we performed experiments using a doxycycline 
(dox) inducible shRNA system that targeted the 3’-untranslated region of DNAJC21. Cell 
lines expressing DNAJC21 3’UTR shRNA were transfected with either eGFP-DNAJC21 or 
the eGFP vector alone. Knockdown of the endogenous protein and the ectopic expression of 
eGFP tagged wild type DNAJC21 (which escapes the effect of the shRNA) were verified by 
immunoblotting (Figure 5E). As expected, re-introduction of wild type DNAJC21 rescued 
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cell viability, restored normal PA2G4 traffic and morphology (Figure 5F and 5G), 
demonstrating that the observed effects were a specific consequence of DNAJC21 depletion. 
 
Discussion 
Although the inherited BMF syndromes have several distinguishing hallmarks, their 
heterogeneous presentation and overlapping features have often confounded their clinical 
diagnosis. However, as the underlying disease associated genes have been discovered, our 
understanding of BMF pathogenesis has improved considerably. Now, in the era of next 
generation sequencing it is possible to identify subgroups of cases, unified by their 
underlying genetic defects. In this study we have used whole exome sequencing to identify a 
distinct subgroup of cases presenting with constitutional BMF unified by defective 
DNAJC21.  
 
We have shown that DNAJC21 associates with precursor 45S rRNA. Cells from affected case 
harbouring biallelic DNAJC21 mutations had reduced levels of precursor 45S and mature 28S 
rRNA and exhibited increased sensitivity to actinomycin D, implicating its role in rRNA 
biogenesis. In addition, DNAJC21 participates in coordinating nucleo-cytoplasmic shuttling 
of PA2G4, to aid in nuclear export of 60S subunit. Our findings from DNAJC21 RNAi 
studies in HeLa cells and cells from an affected case provide compelling evidence in support 
of the hypothesis that loss of DNAJC21 perturbs an essential late cytoplasmic step of the 60S 
subunit maturation, thereby corrupting ribosome biogenesis. Previous studies reported that 
PA2G4 binds to FG repeat nucleoporins through its methionine amino peptidase activity and 
aid in 60S nuclear export.22 In eukaryotic cells, PA2G4 is shown to regulate diverse functions 
such as cell growth and differentiation, interaction with transcription factors,21 ribosome 
biogenesis and rRNA processing 19, 23 as well as IRES-mediated translation.20 Based on these 
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reports it is conceivable that cytoplasmic accumulation of PA2G4 in absence of DNAJC21 
would affect these wide range of diverse functions in human cells. Together, our data clearly 
establishes that the function of DNAJC21 in ribosome biogenesis is highly conserved from 
yeast to humans.13-18 
Altered or reduced ribosome biogenesis has long been implicated in bone marrow failure 
syndromes.5 We now add DNAJC21 to the growing list of ribosomopathies, which are a class 
of disease caused by mutations that affect the biosynthesis and or function of the ribosome.24 
Ribosomopathies are intriguingly enigmatic as they initially present with pathognomonic 
features of too few cells in the marrow but may (in ~ 10-20% of cases) later give rise to 
hyper-proliferative disorders such as acute myeloid leukaemia.5,25 It is notable that this holds 
true for one of the four cases presented here, although with such a small number of affected 
individuals it is difficult to extrapolate this proportion to a larger cohort. While it is likely that 
these cancers arise from a selection pressure resulting in the acquisition of mutations, we also 
believe that a dearth of the 60S ribosome subunit could exert pressure on cells to use 
defective ribosomes. Over time, these cells may become error prone leading eventually to 
transition from a hypo- to a hyper-proliferative phenotype.25, 26  
 
We have identified two distinct areas of operation of DNAJC21, one in nucleolar rRNA 
biogenesis and a second in cytoplasmic recycling of nuclear export factor PA2G4 for 60S 
subunit maturation. We note that the yeast orthologue of human DNAJC21 (Jjj1) acts just 
upstream of the release of Tif6 by Sdo1 in 60S maturation,27 and that the human orthologue 
of Sdo1 is SBDS the protein defective in Shwachman Diamond syndrome.28-31 By analogy 
with SBDS, it is therefore more likely that the disease phenotype in our cases is caused by the 
late 60S maturation deficit. This is also consistent with the suggestion that mutations that 
affect the overall structural integrity of the ribosome are less likely to be tolerated. 26  
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It is striking that two out of the four cases presented here have homozygous nonsense variants 
and we were unable to detect DNAJC21 in the lymphocytes of an affected individual. It 
therefore appears that individuals who lack DNAJC21 remain viable. This is in contrast to 
Shwachman Diamond syndrome cases, where no homozygotes for a recurrent nonsense 
variant have been reported, suggesting that null mutations in SBDS are embryonic lethal.32 
We do note, however, that the small numbers of DNAJC21 cases presented here have global 
BMF by the age of 12 years, while in Shwachman Diamond syndrome the BMF is more 
variable and often only involves an isolated neutropenia.33  
 
In conclusion, our study defines a cancer prone bone marrow failure syndrome caused by 
mutations in DNAJC21. Characterisation of the encoded protein shows that it plays a highly 
conserved role in ribosome biogenesis. We have therefore identified a distinct 
ribosomopathy, highlighting the significance of corrupted ribosomes in the etiology of both 
hypo-proliferative and hyper-proliferative disorders. 
 
Accession codes 
Variants identified in DNAJC21 were deposited in ClinVar database [NCBI/NIH/NLH] under 
accession numbers SCV000257530 SCV000257531 SCV000257532 SCV000257533.  
 
Web Resources 
Variants were compared against the following databases: dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/), the 1000 Genomes (http://www.1000genomes.org/data) 
and the ExaC database (http://www.exac.broadinstitute.org, accessed January 2016). 
Conserved protein domains were identified using 
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http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi. mRNA expression array data was 
extracted from BioGPS (http://www.biogps.org) and GTex (http://www.gtexportal.org). The 
DNAJC213’UTR shRNA targets are obtained from TRC shRNA mission library 
(https://www.broadinstitute.org/rnai/trc/lib) and RNAi designer tool 
(https://rnaidesigner.thermofisher.com/rnaiexpress/setOption.do?designOption=sirna). The 
protocol for Addgene shRNA production was provided at 
http://www.addgene.org/static/data/41/67/165920fc-af64-11e0-90fe-
003048dd6500.pdf.Crystal structure of J domain (PBD id:  1FAF) was obtained from protein 
data bank (http://www.rcsb.org) and visualized using Swiss-PDB viewer (http://spdbv.vital-
it.ch/). 
Online Mendelian Inheritance in Man (http://www.omim.org). 
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Figure Legends 
Figure 1. Biallelic mutations in DNAJC21  
(A) Sanger sequencing traces and the genotype of each case are given. Arrows indicate the 
mutated nucleotides. (B) The positions of the alterations caused by the mutations observed in 
our cases are shown in the context of the conserved functional domains predicted in the 
DNAJC21 amino acid sequence. Residue numbers are given for the different domains. J 
domain refers to DNAJ domain that defines this group of proteins; DBINO refers to the 
DNA-binding domain found on global transcription activator SNF2L1 proteins and chromatin 
re-modelling proteins. The frameshift p.Gly299Alafs*2 is shown in red as it is predicted to 
arise from deletion of exon 7 due to the splice site mutation c.983+1G>T in case 2. (C) 
Conservation of the HPD motif in the J domain of DNAJC21. Alignment of residues 16-50 of 
the human DNAJC21 J domain with four other DnaJ proteins was generated with ClustalW. 
The arrow indicates the proline residue that was mutated in case 3. The aligned sequences are 
human (H.s) DNAJC21 (Q5F1R6), Drosophila melanogaster (D.m) DNAJ-1 (Q53ZT0), rice 
(O.s) Oryza sativa DNAJ homologue (Q948S9), Saccharomyces cerevisiae (S.c) DnaJ-related 
protein SCJ1 (P25303) and Escherichia coli (E.c) chaperone protein DnaJ (P08622). 
Asterisks indicate positions that have a single fully conserved residue, colons indicate 
conservation between groups of strongly similar properties, and periods indicate conservation 
between groups of weakly similar properties. (D) E coli DnaJ domain topology (PDB 
id:1FAF) visualised using swiss PDB viewer. Ribbon diagram depicts J domain (grey), 
position of HPD motif (orange loop). The hydrogen bonds between residues in the HDP 
motif are indicated by dotted line (black). Mimicking the case 3 mutant by in silico analysis 
revealed loss of the proline’s cyclic ring disrupting hydrogen bonds (dotted line,black) when 
substituted with alanine in the J domain. 
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Figure 2. Nucleolar localisation of DNAJC21 and its role in rRNA biogenesis 
(A) DNAJC21 is present in both cytoplasmic (Cy) and nuclear fractions (Nu); WC, whole 
cell. Antibody against TBP was used as control for nuclear fractions. (B)  
Immunocytochemistry shows the subcellular localisation of DNAJC21 in different cell types. 
A lack of DNAJC21 immunostaining is observed in T cells from case 4, while the parental T 
cells stain positive. Nucleophosmin (NPM1) is used as a control. Images display NPM1 
(green), DNAJC21 (red) and DAPI (blue).  Scale bar 20 µm. (C and D) DNAJC21 
translocates to the nucleus following actinomycin D treatment. NPM1 is used as positive 
control. (E) LCLs from Case 4 and asymptomatic heterozygous parent controls (1 and 2) 
were plated in the presence of increasing concentrations of actinomycin D for 48hrs and 
assayed for cell viability by staining with Neutral Red. Assays were performed in octuplets 
per experiment and repeated for a minimum of two independent experiments. (F) Case 4 
LCLs show reduced levels of expression for rRNA in nuclear extracts analysed when 
compared to both parents and 3 unrelated samples as controls.  Expression levels of 
SNORA63 and SNORA68 are determined as internal controls. All genes are normalized 
relative to expression levels of GAPDH mRNA. Data represent mean ± SD, n = 2, performed 
in triplicates.  
 
Figure 3. DNAJC21 associates with rRNA and interacts with 60S ribosome maturation 
factors  
(A) Expression levels of eGFP tagged DNAJC21 wild type and mutants were detected by 
immunoblotting using anti-GFP. GAPDH is used as loading control. (B) 
Immunoprecipitation was performed with GFPTRAP agarose beads and nuclear extracts of 
HeLa cells, expressing wildtype and mutant forms of DNAJC21. EGFP alone expressing 
cells were used as control for the co immunoprecipitation. RNA was extracted from the 
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immunoprecipitates and analysed by RTPCR. Data represent mean ± SD, n = 2 independent 
experiments performed in duplicate. (*P < 0.05, ***P < 0.0001 Mann-Whitney U test). (C) 
Co-immunoprecipitations were performed in HeLa cells expressing eGFP or eGFP-
DNAJC21. Lysates were treated with DNase I or RNase A prior to immunoprecipitation 
where indicated. Co-immunoprecipitated proteins were detected by western blot analysis with 
eGFP, HSPA8, ZNF622 and PA2G4 specific antibodies. (D) Co-immunopreciptation from 
cells expressing eGFP tagged wild type and mutant forms of DNAJC21 reveal the variable 
interaction with co factors involved in 60S ribosome maturation. IN, 10% input; IP, 
immunoprecipitate; WT, wild type. 
 
Figure 4. Loss of DNAJC21 impairs traffic of PA2G4 corrupting ribosome biogenesis  
(A, B, C) Cytoplasmic accumulation of PA2G4 was observed in DNAJC21 knockdown cells 
and T lymphocytes from case 4 when compared to relevant controls. Images (A and C) show 
DAPI (blue), PA2G4 (red). Scale bars 35 µm (panel A) and 20 µm (panel C). Panels indicate 
representative of images taken from different fields of view in three separate experiments. 
Panel B shows immunoblotting of cytoplasmic (C) and nuclear (N) fractions. (D) 
Immunoblotting of LCL lysates from case 4 and parental controls for DNAJC21 and 60S 
maturation factors HSPA8, PA2G4 and ZNF622. (E) Cycloheximide treated lysates from 
case 4 and parent control LCLs as well as DNAJC21 and non-target siRNA treated HeLa 
cells were fractionated on 15% to 45% sucrose gradients by ultracentrifugation. Absorbance 
at 254 nM across the gradient fraction is shown (top panels). Ribosomal subunit ratios 
(60S:80S) are indicated. TCA precipitated proteins from equal aliquots of each fraction were 
immunoblotted for PA2G4 and RPL7 as a marker for 60S and 80S subunits and polysomes. 
Data presented is representative of two independent experiments (n=2) 
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Figure 5. Loss of DNAJC21 inhibits cell growth  
(A) After 72 hours of DNAJC21 siRNA by doxycycline treatment to induce shRNA targeting 
the 3’UTR of DNAJC21 (100ng/ml), whole-cell extracts were subjected to western blot 
analysis using DNAJC21 and GAPDH specific antibodies. (B) FACS plots show increased 
cell death in cells treated with DNAJC21 siRNA.  (C) Phase contrast microscopy images of 
DNAJC21 RNAi treated cells exhibiting abnormal morphology when compared to control. 
All panels are representative of images taken from different fields of view in two separate 
experiments. (D) T lymphocytes from case 4 show impaired growth when compared to 
parental controls. ***, p = <0.001, Student’s t-Test. (E) Knockdown of endogenous 
DNAJC21 by dox administration is detected by western blotting using a mix of both 
DNAJC21 and GFP antibodies in stably transduced DNAJC21 3’UTR shRNA HeLa cells. 
Arrows indicate positions of endogenous DNAJC21 and eGFP control. (F) Cell viability 
relative to an untreated dox (-) culture, was measured by GFP fluorescence. This revealed the 
rescue of cell viability in the presence of eGFP-DNAJC21, upon dox induction of the shRNA 
targeting the endogenous transcript. Data represent mean ± SEM; **P < 0.01 1-way ANOVA 
with Tukey’s post hoc test. (G) In cells expressing eGFP alone, confocal imaging revealed 
cytoplasmic accumulation of PA2G4 and abnormal morphology upon dox administration. 
However, in cells expressing eGFP-DNAJC21 no defect in PA2G4 shuttling to nucleus or 
cell morphology was observed upon dox addition (+) when compared to an untreated dox (-) 
culture.  Images display eGFP (green) and PA2G4 (red). Panels are representative of images 
taken from different fields of view in three separate experiments. Scale bar 20 µm. 
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Table 1. Features of cases with biallelic mutations in DNAJC21  
 
        
Cases Case 1 Case 2  Case 3   Case 4 
Genotype (c.) 517C>T 983+1G>T  94C>G      793G>T 
Protein (p.) Arg173*   Gly299Alafs*2a Pro32Ala   Glu265* 
___________________________________________________________________________ 
Feature 
Gender F F        M    F 
Age when sample received (yrs)  3 6  12    6 
Country of origin France Algeria          Pakistan        Pakistan  
Parents first cousins Y Y  Y    N   
Bone marrow failureb Y Y  Y    Y   
IUGR and/or short stature Y Y  Yc      Y   
Microcephaly Y Y                N              N   
 Other features    N   Yd    Ye       Yf 
 Chromosomal breakageg   N            N        N     N  
TTelom Telomere length h                          Normal         Normal              Normal       Normal 
__________________________________________________________________________ 
 
F = female; M = male; Y = yes; N = no; IUGR = intrauterine growth restriction; a = inferred 
from splice site variant. b = the bone marrow failure was global and was associated with a 
reduction in all cell lineages in the peripheral blood (pancytopenia). Case 3 developed acute 
myeloid leukaemia sub-type megakaryocytic (AML-M7); c = growth hormone defect; d = 
dental abnormalities (microdontia), hyperkeratosis, retinal dystrophy with poor vision; e = 
skin pigmentation abnormalities on feet and dental abnormalities; f = dysphagia/oral 
ulceration; g = following treatment with diepoxybutane or mitomycin C; h = measured by 
monochrome multiplex quantitative PCR.34 
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Supplemental Information 
Supplemental Figures 
Supplemental Figure 1. Expression profile of DNAJC21 
 
 
DNAJC21 is shown to be ubiquitously expressed, as observed by tissue specific mRNA 
expression profiles. Data obtained from two independent sources: BioGPS 
(http://www.biogps.org), left hand panel and GTex (http://www.gtexportal.org), right hand 
panel.  
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Supplemental Figure 2a. DnaJ homolog subfamily C member 21 (DNAJC21, UniProt 
reference Q5F1R6) is the human orthologue of yeast J protein Jjj1 (P53863) 
 
DNAJC21         -MKCHYEALGVRRDASEEELKKAYRKLALKWHPDKNLDNAAEAAEQFKLIQAAYDVLSDP 59 
Jjj1            MKTCYYELLGVETHASDLELKKAYRKKALQYHPDKNPDNVEEATQKFAVIRAAYEVLSDP 60 
                  .*:** ***. .**: ******** **::***** **. **:::* :*:***:***** 
 
DNAJC21         QERAWYDNHREALLKGG-------FDGEYQD-----DSLDLLRYFTVTCYSGYGDDEKGF 107 
Jjj1            QERAWYDSHKEQILNDTPPSTDDYYDYEVDATVTGVTTDELLLFFNSALYTKIDNSAAGI 120 
                *******.*:* :*:.        :* * :       : :** :*. : *:  .:.  *: 
 
DNAJC21         YTVYRNVFEMIAKEELES-------------VLEEEVD------------------DFPT 136 
Jjj1            YQIAGKIFAKLAKDEILSGKRLGKFSEYQDDVFEQDINSIGYLKACDNFINKTDKLLYPL 180 
                * :  ::*  :**:*: *             *:*::::                   :*  
 
DNAJC21         FGDSQSDYDTVVHPFYAYWQSFCTQKNFAWKEEYDTRQASNRWEKRAMEKENKKIRDKAR 196 
Jjj1            FGYSPTDYEYLKH-FYKTWSAFNTLKSFSWKDEYMYSKNYDRRTKREVNRRNEKARQQAR 239 
                ** * :**: : * **  *.:* * *.*:**:**   :  :*  ** :::.*:* *::** 
 
DNAJC21         KEKNELVRQLVAFIRKRDKRVQAHRKLVEEQN--AEKARKAEEMRRQQKLKQAKLVEQYR 254 
Jjj1            NEYNKTVKRFVVFIKKLDKRMKEGAKIAEEQRKLKEQQRKNELNNRRKFGNDNNDEEKFH 299 
                :* *: *:::*.**:* ***::   *:.***.   *: ** *  .*::  :: :  *::: 
 
DNAJC21         EQSWMTMANLEKELQEMEARYEKEFGDGSDENE---------------MEEHELK---DE 296 
Jjj1            LQSWQTVKEENWDELEKVYDNFGEFENSKNDKEGEVLIYECFICNKTFKSEKQLKNHINT 359 
                 *** *: : : :  *       ** :..:::*                .*::**   :  
 
DNAJC21         EDGKDSDEAEDAELYDDLYCPACDKSFKTEKAMKNHEKSK-KHREMVALLKQQLEEEEEN 355 
Jjj1            KLHKKNMEEIRKEMEEENITLGLDNLSDLEKFDSADESVKEKEDIDLQALQAELAEIERK 419 
                :  *.. *    *: ::    . *:  . **  . .*. * *.   :  *: :* * *.: 
 
DNAJC21         FSRPQIDENPLDDNS----EEEMEDAPKQKLSKKQKKKKQKPAQNYDDNFNVNGPGEGVK 411 
Jjj1            LAESSSEDESEDDNLNIEMDIEVEDVSSDENVHVNTKNKKKRKKKKKAKVDTETE-ESES 478 
                ::... :::. ***     : *:**...::  : :.*:*:*  :: . :.:.:   *. . 
 
DNAJC21         VDPEDTNLNQDSAKELEDSPQENVSVTEIIKPCDDPKSEAKSVPKPKGKKTKDMKKPVRV 471 
Jjj1            FDDTKDKRSNELDDLLASLGDKGLQTDDDEDWSTKAKKKKGKQPKKNSKSTKSTPSLSTL 538 
                .*  . : .::  . * .  ::.:.. :  . . ..*.:  . ** :.*.**.  .   : 
 
DNAJC21         PAEPQTMSVLISCTTCHSEFPSRNKLFDHLKATGHARAPSSSSLNSATSSQSKKEKRKNR 531 
Jjj1            PSSMSPTSAIEVCTTCGESFDSRNKLFNHVKIAGHAAVKN------VVKRKKVKTKRI-- 590 
                *:. .. *.:  **** ..* ******:*:* :*** . .      ... :. * **    
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Supplemental Figure 2b. Proliferation-associated protein 2G4 (PA2G4, UniProt 
reference Q9UQ80) is the human orthologue of yeast probable metalloprotease Arx1 
(Q03862)  
 
PA2G4           ----MSGEDEQ---QEQTIAEDLVVTKYKMGGDIANRVLRSLVEAS---------SSGVS 44 
Arx1            MALAISHEDTQILLKDKNILQESVLNKYRTAGQIAQTALKYVTSLINDSYHSKTTQRQLT 60 
                    :* ** *   :::.* :: *:.**: .*:**: .*: :..           .  :: 
 
PA2G4           VLSLCEKGDAMIMEETGKIFKKEKEMKKGIAFPTSISVNNCVCHFSPLKSDQD------- 97 
Arx1            VPELCLLTDSFILTRLEQYYKN-KVNERGIAIPTTIDIDQISGGWCPEIDDTQNLLNWNK 119 
                * .**   *::*: .  : :*: *  ::***:**:*.:::    :.*  .* :        
 
PA2G4           -----------YILKEGDLVKIDLGVHVDGFIANVAHTFVVDVAQGTQ--------VTGR 138 
Arx1            GKDSTFASSVTGTLRPGDLVKITLGVHIDGYTSEVSHTMVIYPVDETKPILQPTGPLLGG 179 
                             *: ****** ****:**: ::*:**:*:  .: *:        : *  
 
PA2G4           KADVIKAAHLCAEAALRLVKPGNQNTQVTEAWN----------------KVAHSFNCTPI 182 
Arx1            KADAVAAAHIAMETVVALLACALTPEKLPASLGGTSSGITGQLIRTIVDTIARSYNCGVV 239 
                ***.: ***:. *:.: *:  .    ::. : .                .:*:*:**  : 
 
PA2G4           EGMLSHQLKQHVIDGEKTIIQN------------------------------------PT 206 
Arx1            PGSRVRRIRRFLAGQNEGIVAEREYKGVVWTESHQEADLLSNTDAKDLTVVDRGQSTPFT 299 
                 *   :::::.: . :: *: :                                     * 
 
PA2G4           DQQKKDHEKAEFEVHEVYAVDVLVSSGE-----------------GKAKDAG---QRTTI 246 
Arx1            NVSAIPSDDFVVQSGEVYLIDLKMASLEHCTKKGLVTLETVDSYTGKSHKAGELIARPGA 359 
                : .    :.  .:  *** :*: ::* *                 **::.**    *.   
 
PA2G4           YKRDPSKQYGLKMKTSRAFFSEVERR----------FDAMPFTLRAFE-------DEKKA 289 
Arx1            YVRDFAQTHILKLKTSRQLLTKIDKQGVYPFKLSHLSSNFPFVHENEEELQSLKKDLKSF 419 
                * ** :: : **:**** ::::::::           . :**. .  *       * *.  
 
PA2G4           RMGVVECAK------------------------------------------HELLQP--- 304 
Arx1            RLGMSEISNNYLCVESPIQIARWVPWDHILKATNPNGNLSYDATSTLTLPGHELPLPKLG 479 
                *:*: * ::                                          ***  *    
 
PA2G4           ---------FNVLYEKEGEFVAQFKFTVLLMPNGP--------MRITSG--PFEPDLYKS 345 
Arx1            VSAIKLKSLMNSTKESISLPVARECNTIVLCDSSVSTTDRPELLRLTGGSKTCQPSWIHS 539 
                         :*   *. .  **:   *::*  ..         :*:*.*  . :*.  :* 
 
PA2G4           --EMEVQDAELKALLQSSASRKTQKK----KKKKASKTAENATSGETLEENEAGD 394 
Arx1            QHELNPQDSIVQGIFQLATLAKDKRFGLLLKETQPMKQKSVETSNGGVEETMKM- 593 
                  *:: **: ::.::* ::  * ::     *:.:. *  .  **.  :**.     
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Supplemental Figure 2c. Zinc finger protein 622 (ZNF622, UniProt reference Q969S3) 
is the human orthologue of yeast cytoplasmic 60S subunit biogenesis factor Rei1 
(P38344) 
  
ZNF622          ---MATYTCITCRVAFRDADMQRAHYKTDWHRYNLRRKVASMAPVTAEGFQERVRAQRAV 57 
Rei1            MSSSGVYTCNSCVLTFDSSDEQRAHMKSDWHRYNLKRRVAQLPPISFETFDSKVSAAAAS 60 
                    ..*** :* ::* .:* **** *:*******:*:**.:.*:: * *:.:* *  *  
 
ZNF622          AEEESKGSATYCTVCSKKFASFNAYENHLKSRRHVELEKKAVQAVNRKVEMMNEKNLEKG 117 
Rei1            TSKSAEK------------------EKPVTKKELKRREKQALLEKKKKLLEIARAN---- 98 
                :.:.::                   *: :..:.  . **:*:   ::*:  : . *     
 
ZNF622          LGVDSVDKDAMNAAIQQAIKAQPSMSPKKAPPAPAKEARNVVAVGTGGRGTHDRDPSEKP 177 
Rei1            -------------MLENMQKSQEGNTP--------------------------------- 112 
                              :::  *:* . :*                                  
 
ZNF622          PRLQWFEQQAKKLAKQQEEDSEEEEEDLDGDDWEDIDSDEELECEDTEAMDDVVEQDAEE 237 
Rei1            --------DLSKLSLQENEENKEKEE----------PKKEEPEQLTEEEMAERVMQEKLR 154 
                        : .**: *::*:.:*:**           ..** *    * * : * *:  . 
 
ZNF622          EEAEEGPPLGAIPITDCLFCSH--HSSSLMKNVAHMTKDHSFFIPDIEYLSDIKGLIKYL 295 
Rei1            NRVD-------IPLEQCLFCEHNKHFKDVEENLEHMFRTHGFYIPEQKYLVDKIGLVKYM 207 
                :..:       **: :****.*  * ..: :*: ** : *.*:**: :** *  **:**: 
 
ZNF622          GEKVGVGKICLWCNEKGKSFYSTEAVQAHMNDKSHCKLFTDG-DAALEFADFYDFRSSYP 354 
Rei1            SEKIGLGNICIVCNYQGR---TLTAVRQHMLAKRHCKIPYESEDERLEISEFYDFTSSYA 264 
                .**:*:*:**: ** :*:   :  **: **  * ***:  :. *  **:::**** ***. 
 
ZNF622          DHKEGEDPNKAEELPSEKNLEYDDET------------MELILPSGARVGHRSLMRYYKQ 402 
Rei1            NFNSNTTPDNEDDWEDVGSDEAGSDDEDLPQEYLYNDGIELHLPTGIKVGHRSLQRYYKQ 324 
                :.:..  *:: ::  .  . * ..:             :** **:* :****** ***** 
 
ZNF622          RFGLSRAVAVAKNRKAVGRVLQQYRALGWTGSTGAALMRERDMQYVQRMKSKWMLKTGMK 462 
Rei1            DLKPEVILTEGQGTLVAAETRSFLPAFDKKG-----VQTQQRVWQTERFDKKRLDKRSAK 379 
                 :  .  :: .:.  ..... .   *:. .*     :  :: :  .:*:..* : * . * 
 
ZNF622          NNATKQMHFRVQVRF 477 
Rei1            -FVNNQPHYRDQLLQ 393 
                  ..:* *:* *:   
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Supplemental Figure 2d. Heat shock cognate 71 kDa protein HSPA8 (UniProt reference 
P11142) is the human orthologue of yeast heat shock protein Ssa1 (P10591)  
 
HSPA8           MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVA 60 
Ssa1            MSK--AVGIDLGTTYSCVAHFANDRVDIIANDQGNRTTPSFVAFTDTERLIGDAAKNQAA 58 
                ***  *************. * :.:*:*************:*****************.* 
 
HSPA8           MNPTNTVFDAKRLIGRRFDDAVVQSDMKHWPFMVVNDAGRPKVQVEYKGETKSFYPEEVS 120 
Ssa1            MNPSNTVFDAKRLIGRNFNDPEVQADMKHFPFKLIDVDGKPQIQVEFKGETKNFTPEQIS 118 
                ***:************.*:*. **:****:** :::  *:*::***:*****.* **::* 
 
HSPA8           SMVLTKMKEIAEAYLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTAAA 180 
Ssa1            SMVLGKMKETAESYLGAKVNDAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTAAA 178 
                **** **** **:*** .*.:*************************************** 
 
HSPA8           IAYGLDKKVGAERNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDTHLGGEDFDNRMVNH 240 
Ssa1            IAYGLDKK-GKEEHVLIFDLGGGTFDVSLLSIEDGIFEVKATAGDTHLGGEDFDNRLVNH 237 
                ******** * *.:**************:*:*********:***************:*** 
 
HSPA8           FIAEFKRKHKKDISENKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGIDFYTSITRA 300 
Ssa1            FIQEFKRKNKKDLSTNQRALRRLRTACERAKRTLSSSAQTSVEIDSLFEGIDFYTSITRA 297 
                ** *****:***:* *:**:*****************:*:*:*****:************ 
 
HSPA8           RFEELNADLFRGTLDPVEKALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELN 360 
Ssa1            RFEELCADLFRSTLDPVEKVLRDAKLDKSQVDEIVLVGGSTRIPKVQKLVTDYFNGKEPN 357 
                ***** *****.*******.**********:.:************:***: *:***** * 
 
HSPA8           KSINPDEAVAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVMTVLIKRNTTI 420 
Ssa1            RSINPDEAVAYGAAVQAAILTGDESSKTQDLLLLDVAPLSLGIETAGGVMTKLIPRNSTI 417 
                :*******************:**:*.:.********:************** ** **:** 
 
HSPA8           PTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLLGKFELTGIPPAPRGVPQIEVTFDI 480 
Ssa1            PTKKSEIFSTYADNQPGVLIQVFEGERAKTKDNNLLGKFELSGIPPAPRGVPQIEVTFDV 477 
                ***::: *:**:**********:***** ************:*****************: 
 
HSPA8           DANGILNVSAVDKSTGKENKITITNDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKN 540 
Ssa1            DSNGILNVSAVEKGTGKSNKITITNDKGRLSKEDIEKMVAEAEKFKEEDEKESQRIASKN 537 
                *:*********:*.***.******************:** ****:* ****: ::::*** 
 
HSPA8           SLESYAFNMKATVEDEKLQGKINDEDKQKILDKCNEIINWLDKNQTAEKEEFEHQQKELE 600 
Ssa1            QLESIAYSLKNTIS--EAGDKLEQADKDTVTKKAEETISWLDSNTTASKEEFDDKLKELQ 595 
                .*** *:.:* *:.  :  .*::: **:.: .*.:* *.***.* **.****:.: ***: 
 
HSPA8           KVCNPIITKLYQS---AGGMPGGMPGGFPGGGAPPSGGASSGPTIEEVD 646 
Ssa1            DIANPIMSKLYQAGGAPGGAAGGAPGGFPGG-APPAP-EAEGPTVEEVD 642 
                .:.***::****:   .** .** ******* ***:   :.***:**** 
 
ClustalW alignment shows the homology of human (a) DNAJC21, (b) PA2G4, (c) HSPA8 
and (d) ZNF622 to yeast counterparts, Jjj1, Arx1, SSa1 and Rei1. Asterisks indicate positions 
that have a single fully conserved residue, colons indicate conservation between groups of 
strongly similar properties, and periods indicate conservation between groups of weakly 
similar properties. 
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Supplemental Figure 3. Cytoplasmic eviction of PA2G4 from 60S ribosome subunit 
upon stimulation of ATPase activity 
 
A schematic model of the PA2G4 release process depicted on the basis of studies reported in 
yeast by Greber et al 2012. In the nucleus, PA2G4 binds and exports the pre 60S ribosome 
particle. In the cytoplasm, DNAJC21 and ZNF622 bind the pre-60S particle, establishing a 
network of interactions that enable the recruitment of HSPA8. The stimulation of the HSPA8 
ATPase by DNAJC21 leads to dissociation of PA2G4, enabling it to recycle back into 
nucleus (red dotted arrow). 
 
 
 
 
 
 
 
 
Supplemental Figure 4. Inducible knockdown of DNAJC21 
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(a) Sequences of shRNA’s targeting the 3’UTR of DNAJC21. (b) HeLa cell lines transduced 
with four independent inducible shRNA’s targeting DNAJC21 3’UTR were cultured by the 
addition of doxycycline to the growth media. 72 hours post-induction cells were analysed by 
Western blot using a DNAJC21 antibody. GAPDH served as a loading control. 
 
References 
 Greber BJ, Boehringer D, Montellese C & Ban N. Cryo-EM structures of Arx1 and 
maturation factors Rei1 and Jjj1 bound to the 60S ribosomal subunit. 2012. Nat. 
Struct. Mol. Biol 19, 1228-1233. 
40 
 
Supplemental Table 1. Somatic features of patients with BMF (exome sequencing) 
Age Sex Somatic features 
2 F Developmental delay, failure to thrive 
14 M Alopecia, nail pitting 
37 M Hypopigmented skin, nail ridging 
11 F Immunodeficiency, enteropathy 
4 M Developmental delay, thin hair, café au lait spot, recurrent infections 
25 F Leukoplakia, asceptic necrosis  
1 M Developmental delay   
7 M Developmental delay, hypopigmented skin patches 
6 F Short stature, microcephaly, dental abnormalities, hyperkeratosis, retinal dystrophy 
(case 2) 
11 F Short stature, IUGR, hair loss, abnormal faces, extensive caries 
66 F Short stature, hair loss, dental loss, pulmonary disease 
4 F Dysmorphic features 
41 F Nail dystrophy 
1 M Dysmorphic features, skin lesions, hepatomegaly, splenomegaly 
30 F Short stature, psychiatric problems, nail dystrophy 
22 M Abnormal skin pigmentation, hair loss, dental caries 
12 M Short stature, abnormal skin pigmentation, dental abnormalities (case 3) 
28 M Short stature, cardiac hypertrophy, skeletal abnormality, cirrhosis 
32 M Marfanoid, syndactyly, learning difficulties, epilepsy, immunodeficiency 
15 F Dysmorphic face,  learning difficulties, epilepsy, misaligned teeth 
16 M Nail dystrophy 
11 F Low birth weight, telangiectasia, white hair 
3 F Short stature, microcephaly (case 1) 
57 M Pulmonary fibrosis 
2 M Global developmental delay 
22 F Developmental delay, SS. Small eyes 
10 M Mental retardation, discoloured teeth, hyperkeratotic nails, ichthyotic legs 
43 F Grey hair 
IUGR = intrauterine growth restriction 
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Supplemental Table 2. Somatic features of patients with BMF (targeted resequencing) 
Age  Sex Somatic features 
39 M Nail dystrophy 
61 M Idiopathic pulmonary fibrosis, abnormal hands 
 6  F Short stature, oral ulceration/dysphagia (case 4)  
42 F Short stature, abnormal skin pigmentation 
30 M Abnormal skin pigmentation, short thumbs, splenomegaly 
36 F Short stature  
7 F Developmental delay, autistic features, alopecia, crumbling nails,  
58 F Bilateral deafness, infertility 
60 M Early grey 
12 M Short stature, skeletal abnormality 
50 M Nail dystrophy 
2 M Abnormal liver function, very short telomeres 
19 F Short stature, learning difficulties, moles, nail dystrophy, cerebellar 
hypoplasia 
24 M Avascular necrosis, eczema, squint 
58 F Hair loss, no eyebrows, nail dystrophy 
33 F Short stature, abnormal faces 
32 M Learning difficulties, inflammatory polyps 
45 F Nail dystrophy 
14 M Poor teeth 
7 M Enteropathy, hepatosplenomegaly, café au lait spot, pancreatic atrophy 
42 M Short stature, dysmorphic faces, stubby hands, nail dystrophy 
63 F Skin pigmentation, nail ridging, extensive caries 
13 F Colectomy, recurrent infections, liver dysfunction, poor dentition 
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Supplementary Table 3. rRNA primers 
45S_fwd  CGCCGCGCTCTACCTTACCTA 
45S_rev  TAGGAGAGGAGCGAGCGACCA 
18S_fwd CTGCCCTATCAACTTTCGATGGTAG 
18S_rev  CCGTTTCTCAGGCTCCCTCTC 
28S_fwd  TGTCGGCTCTTCCTATCATTGT 
28S_rev  ACCCAGCTCACGTTCCCTATTA 
 
 
 
 
 
